Guideline Lays Out Parallel Review Timeline for Drug Development in EU

Manufacturers looking to speed up drug approvals in the EU and ensure that their products are covered by payers should initiate parallel conversations with the European Medicines Agency and health technology assessment bodies early in the development process, the EMA says.
International Pharmaceutical Regulatory Monitor